Automatic arterial input function (AIF) area determination is provided that can be used to facilitate the generation of parametric maps for perfusion studies based on various imaging modalities and covering a variety of tissues. Automatic AIF determination can be accomplished by extracting characteristic parameters such as maximum slope, maximum enhancement, time to peak, time to wash-out, and wash-out slope. Characteristic parameter maps are generated to show relationships among the extracted characteristic parameters, and the characteristic parameter maps are converted to a plurality of two-dimensional plots. Automated segmentation of non-AIF tissues and determination of AIF areas can be accomplished by automatically finding peaks and valleys of each phase of AIF areas on the plurality of two-dimensional plots.
An apparatus and methodological framework are provided, named perfusionangiography, for the quantitative analysis and visualization of blood flow parameters from DSA images. The parameters, including cerebral blood flow (CBF) and cerebral blood volume (CBV), mean transit time (MTT), time-to-peak (TTP), and Tmax, are computed using a bolus tracking method based on the deconvolution of time-density curves on a pixel-by-pixel basis. Individual contrast concentration curves of overlapping vessels can be delineated with multivariate Gamma fitting. The extracted parameters are each transformed into parametric maps of the target that can be color coded with different colors to represent parameter values within a particular set range. Side by side parametric maps with corresponding DSA images allow expert evaluation and condition diagnosis.
The invention discloses a pavement material with a wide phase change temperature zone and a preparation method thereof. The pavement material comprises a shape-stabilized phase change material and asphalt, wherein a mass ratio of the shape-stabilized phase change material to the asphalt is 1:(5-20); the shape-stabilized phase change material is prepared by mixing tetradecane / carrier, pentadecane / carrier, hexadecane / carrier, heptadecane / carrier, octodecane / carrier, nonadecane / carrier, eicosane / carrier and polyethylene glycol / carrier; and a mass ratio is 1:1:(1-3):(1-3):(1-3):(1-3):1:1. The shape-stabilized phase change material of different phase change temperatures is doped into the asphalt, so that the asphalt concrete pavement temperature is regulated, the adaptability on the outside temperature change is enhanced, the temperature rise rate inside large-volume asphalt concrete is effectively reduced, time-to-peak force is delayed, the influence of freezing-thawing cycle and extremely high or low temperature on the concrete pavement performance is reduced, thermal cracks occurring in the asphalt concrete can be prevented, the durability of the material is improved, and the service life is prolonged.
Described here are systems and methods for estimating shear wave velocity from data acquired with a shear wave elastographysystem. More particularly, the systems and methods described here implement a spatiotemporal time-to-peak algorithm that searches for the times at which shear wave motion is at a maximum while also searching for the lateral locations at which shear wave motion is at a maximum. Motion can include displacement, velocity, or acceleration caused by propagating shear waves. A fitting procedure (e.g., a linear fit) is performed on a combined set of these temporal peaks and spatial peaks to estimate the shear wave velocity, from which mechanical properties can be computed. Motion amplitude thresholding can also be used to increase the number of points for the fitting.
The invention discloses a slow release capsule of trimebutine or the salt thereof and a preparation method thereof. The slow release capsule of trimebutine or the salt thereof is prepared by adding the accessories of filler, adhesive and slow release materials and the like into the trimebutine, wherein, the trimebutine can be replaced by the maleate thereof or other medicinal salts. The slow release capsule of trimebutine or the salt thereof can be obtained through the following preparation processes: a pill core is first prepared by adopting microcrystallinecellulose or starch and the like through centrifugation, spray cementing, powder supply, polishing and other processes and coated with a medicated layer to prepare a medicated pill core, which is then coated with a slow release film to make a trimebutine slow release mini-pill, finally the slow release capsule of trimebutine or the salt thereof is obtained after filling the mini-pill in a capsule. Compared with the common preparation, the slow release capsule can continue with drug delivery for up to 12 hours, and has comparably stable blood concentration and long time to peak. And the preparation method of the capsule is characterized by good repeatability and easy operation and the like.
The invention discloses an active ingredient composition for treating alcoholic liver injury, and relates to an active ingredient composition for treating liver injury. The invention solves the problems that the conventional traditional Chinese medicines and compound decoction thereof for treating liver injury are inconvenient to use, and the dosage and safety are difficult to control. The active ingredient composition for treating the alcoholic liver injury consists of 6,7-dimethoxybenzopyran-2-one, geniposide and parietic acid. The active ingredient composition for treating the alcoholic liver injury has the advantages that: the clinical medicinal dosage is accurate, safe and effective, the active ingredient composition is convenient to use, the treatment effect is improved, medicinal materials are saved, and toxic and side effects are reduced; and the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid have liver-protecting and gut-benefiting components having the advantages of quick absorption (short time to peak), slow metabolism (longer half life of medicines), higher peak concentration and larger blood concentration area under a curve, so the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid can serve as preferred active ingredients. The active ingredient composition provides a basis for subsequently preparing finished pharmaceutical products in various formulations.
A reconstruction processor(24) reconstructs diagnostic data from a diagnostic imaging device, such as a CT scanner(10), starting before a contrast agent reaches a region of interest(50), as the concentration of contrast agent in the region of interest builds(52), and at a contrast agent peak(56). The plurality of images generated while the contrast agent concentration is building are aligned(78). A change map is generated indicative of a rate-of-change(62) gradient or a time-to-peak(64) for corresponding pixels or voxels of the images generated during the time the contrast agent is building to the peak. A segmentation processor(70) uses the change map in segmenting the diagnostic images generated without contrast agent or at the contrast agent concentration peak.
The invention belongs to the technical field of medicine, and particularly relates to a chlorpheniramine maleate compound and a pharmaceutical composition of the chlorpheniramine maleate compound. The chlorpheniramine maleate compound has a chemical structure formula seen in the formula (I) and is measured through an X-ray power diffraction measurement method, and an X-ray power diffraction pattern which is expressed by a diffraction angle of 2 theta+ / -0.2 degrees can be seen in the drawing 1. The chlorpheniramine maleate compound is a new crystal form compound different from existing chlorpheniramine maleate in the prior art. The time to peak and the half-life period of chlorpheniramine in pseudoephedrinehydrochloride and chlorphenamine maleate tablets prepared through the new crystal form compound are obviously shortened, the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of ibuprofen and the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of the pseudoephedrinehydrochloride are reduced, time for allowing concentration of active ingredients of the three types of medicine in blood to reach the effective concentration and time for allowing activity of the active ingredients of the three types of medicine to fade away are kept the same as much as possible, and therefore the pharmacological function of the pseudoephedrinehydrochloride and chlorphenamine maleate tablets is enhanced cooperatively.
The invention discloses a sofosbuvirdispersible tablet and a preparation method thereof. The dispersible tablet consists of the following components in percentage by mass: 30-70% of sofosbuvir, which serves as a raw material, and 40-90% of adjuvants, wherein the adjuvants include a filler, a disintegrating agent and a lubricating agent; and the preparation method comprises processes of weighing the raw material and the adjuvants, mixing the raw material and the adjuvants and tableting an obtained mixture. The dispersible tablet prepared by the invention can be completely disintegrated rapidly, so that a time to peak is shortened and drug absorbency; the dispersible tablet has the characteristics of being convenient to take, rapid in efficacy release, high in bioavailability and the like; and the preparation method is simple in process, easy for control, convenient to operate and suitable for industrial production.
The invention belongs to the technical field of medicine, and particularly relates to a chlorpheniramine maleate compound and a pharmaceutical composition of the chlorpheniramine maleate compound. The chlorpheniramine maleate compound has a chemical structure formula seen in the formula (I) and is measured through an X-ray power diffraction measurement method, and an X-ray power diffraction pattern which is expressed by a diffraction angle of 2 theta+ / -0.2 degrees can be seen in the drawing 1. The chlorpheniramine maleate compound is a new crystal form compound different from existing chlorpheniramine maleate in the prior art. The time to peak and the half-life period of chlorpheniramine in pseudoephedrinehydrochloride and chlorphenamine maleate tablets prepared through the new crystal form compound are obviously shortened, the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of ibuprofen and the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of the pseudoephedrinehydrochloride are reduced, time for allowing concentration of active ingredients of the three types of medicine in blood to reach the effective concentration and time for allowing activity of the active ingredients of the three types of medicine to fade away are kept the same as much as possible, and therefore the pharmacological function of the pseudoephedrinehydrochloride and chlorphenamine maleate tablets is enhanced cooperatively.
The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.
The invention discloses an active ingredient composition for treating alcoholic liver injury, and relates to an active ingredient composition for treating liver injury. The invention solves the problems that the conventional traditional Chinese medicines and compound decoction thereof for treating liver injury are inconvenient to use, and the dosage and safety are difficult to control. The active ingredient composition for treating the alcoholic liver injury consists of 6, 7-dimethoxybenzopyran-2-one, geniposide and parietic acid. The active ingredient composition for treating the alcoholic liver injury has the advantages that: the clinical medicinal dosage is accurate, safe and effective, the active ingredient composition is convenient to use, the treatment effect is improved, medicinal materials are saved, and toxic and side effects are reduced; and the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid have liver-protecting and gut-benefiting components having the advantages of quick absorption (short time to peak), slow metabolism (longer half life of medicines), higher peak concentration and larger blood concentration area under a curve, so the 6, 7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid can serve as preferred active ingredients. The active ingredient composition provides a basis for subsequently preparing finished pharmaceutical products in various formulations.